Publication: Epidermal growth factor receptor mutation status in the treatment of non-small cell lung cancer: Lessons learned
Issued Date
2015-01-01
Resource Type
ISSN
20059256
15982998
15982998
Other identifier(s)
2-s2.0-84946714946
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Cancer Research and Treatment. Vol.47, No.4 (2015), 549-554
Suggested Citation
Dae Ho Lee, Vichien Srimuninnimit, Rebecca Cheng, Xin Wang, Mauro Orlando Epidermal growth factor receptor mutation status in the treatment of non-small cell lung cancer: Lessons learned. Cancer Research and Treatment. Vol.47, No.4 (2015), 549-554. doi:10.4143/crt.2014.362 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/35633
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Epidermal growth factor receptor mutation status in the treatment of non-small cell lung cancer: Lessons learned
Other Contributor(s)
Abstract
© 2015 by the Korean Cancer Association. Advances in oncology research have led to identification of tumor-specific biomarkers, some of which are important predictive indicators and ideal targets for novel therapeutics. One such biomarker in non-small cell lung cancer (NSCLC) is the epidermal growth factor receptor (EGFR). Patients with NSCLC who harbor an activating EGFR mutation show a more favorable response to treatment with an EGFR inhibitor, such as gefitinib, erlotinib, or afatinib, than to chemotherapy. The prevalence of EGFR mutations in East Asian patients is higher than that in other populations, and in some clinical settings, patients have been treated with EGFR inhibitors based on clinicopathologic characteristics with no information on EGFR status. However, based on results from a series of studies in which East Asian patients with advanced non-squamous NSCLC were treated with EGFR inhibitors alone or in combination with standard chemotherapy, this may not be the best practice because EGFRmutation status was found to be a key predictor of outcome. Data from these studies highlight the necessity of EGFR testing in determining the most suitable treatment for patients with advanced or metastatic NSCLC.